Retension Pharmaceuticals (NASDAQ:RTSN – Get Free Report) posted its earnings results on Wednesday. The company reported ($7.33) EPS for the quarter, Zacks reports.
Retension Pharmaceuticals Price Performance
Shares of Retension Pharmaceuticals stock traded up $0.74 during trading on Wednesday, hitting $12.15. 32,365 shares of the company’s stock were exchanged, compared to its average volume of 121,834. Retension Pharmaceuticals has a 52-week low of $9.66 and a 52-week high of $18.64.
Analyst Ratings Changes
Several analysts have recently commented on RTSN shares. Wall Street Zen upgraded Retension Pharmaceuticals to a “hold” rating in a report on Saturday. Zacks Research started coverage on Retension Pharmaceuticals in a research report on Wednesday, November 4th. They set a “hold” rating on the stock. Guggenheim started coverage on Retension Pharmaceuticals in a research note on Monday, November 2nd. They issued a “buy” rating and a $55.00 price target for the company. Oppenheimer initiated coverage on Retension Pharmaceuticals in a research note on Tuesday, November 3rd. They set an “outperform” rating and a $50.00 price target on the stock. Finally, Leerink Partners initiated coverage on shares of Retension Pharmaceuticals in a research report on Tuesday, November 3rd. They issued a “strong-buy” rating for the company. One research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, Retension Pharmaceuticals presently has a consensus rating of “Buy” and a consensus target price of $52.50.
Read Our Latest Analysis on Retension Pharmaceuticals
Insider Buying and Selling
In other news, Director Franklin M. Berger acquired 10,000 shares of the company’s stock in a transaction dated Tuesday, October 13th. The shares were acquired at an average price of $12.00 per share, with a total value of $120,000.00. Following the purchase, the director directly owned 10,000 shares of the company’s stock, valued at $120,000. This trade represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Eric L. Keller bought 20,800 shares of the business’s stock in a transaction dated Tuesday, October 13th. The shares were purchased at an average cost of $12.00 per share, with a total value of $249,600.00. Following the completion of the acquisition, the chief executive officer owned 423,377 shares in the company, valued at approximately $5,080,524. This represents a 5.17% increase in their ownership of the stock. The SEC filing for this purchase provides additional information.
About Retension Pharmaceuticals
We are a clinical-stage biopharmaceutical company focused on developing medicines for the treatment of hypertension and other cardiovascular diseases. Our product candidate, RTN-001, is a next-generation, once-daily, oral, small molecule phosphodiesterase-5 (“PDE-5”) inhibitor designed to reduce blood pressure by potentiating nitric oxide signaling, a key mechanism underlying the development and severity of hypertension. While first-generation PDE-5 inhibitors, such as Viagra (sildenafil), were originally studied in cardiovascular indications such as hypertension and angina, we believe they did not have adequate bioavailability and tissue penetration to impact the smooth muscle cells of the central vascular and cardiac tissues and thus failed to achieve clinically meaningful reductions in blood pressure.
See Also
- Five stocks we like better than Retension Pharmaceuticals
- General Motors Faces a Cost Squeeze as Factory Automation Takes Center Stage
- 5 Consumer Discretionary Plays Showing Strength During the Tech Sell-Off
- NVIDIA’s Earnings Were Strong, But Can the Next CEO Keep the Momentum Going?
- SpaceX’s Historic Starship Catch Raises a Bigger Question About Its AI Spending
Receive News & Ratings for Retension Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retension Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
